Codeine; Promethazine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of

What are the differences between vardenafil and tadalafil?

Cabotegravir; Rilpivirine: (Moderate) Concomitant use of vardenafil and rilpivirine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. The degree of QT prolongation associated with rilpivirine is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 3 times the maximum recommended dose. Ceritinib: (Major) Do not use vardenafil orally disintegrating tablets with ceritinib due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A; ceritinib is a strong levitra spray CYP3A inhibitor. Use of vardenafil with other strong CYP3A inhibitors increased the AUC of vardenafil by 10 to 16-fold.

Are you currently using Vardenafil (Levitra, Staxyn)?

There may also be an increased potential for QT prolongation. Vardenafil can produce an increase in QTc interval at both therapeutic and supratherapeutic doses. Ceritinib has been reported to cause concentration-dependent QT prolongation. Periodically monitor ECGs and electrolytes during concurrent use of ceritinib and vardenafil oral tablets. Chloramphenicol: (Major) Do not use vardenafil orally disintegrating tablets with chloramphenicol due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. QT/QTc prolongation and torsade de pointes cost levitra costco (TdP) in some patients.

Vardenafil requires a prescription; self-medicating is unsafe.
Take Levitra approximately 60 minutes before intimacy.
Do not take more than one dose per 24 hours.
Symptoms like priapism need immediate medical attention.
Levitra may cause nasal congestion or upset stomach.
Combining vardenafil with other ED drugs increases risks.
Alcohol can hinder the effectiveness of Levitra.
Levitra is designed for occasional use, not daily.
Precautions include monitoring for vision changes.
Seek medical advice if you experience allergic reactions.

Conivaptan: (Major) Do not use vardenafil orally disintegrating tablets with conivaptan due to increased vardenafil exposure;

Vardenafil Levitra is a prescription medication for erectile dysfunction.
It works by increasing blood flow to the penis.
Vardenafil is marketed under the brand name Levitra.
It typically takes about 25-60 minutes to work.
The effects of vardenafil last up to 4-5 hours.
It should be taken on an empty stomach for faster results.
Common side effects include headache and flushing.
Vardenafil is contraindicated with nitrates.
Do not consume alcohol with vardenafil.
Always follow your doctor's dosage instructions.

do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets.

Levitra is manufactured by Bayer Pharmaceuticals.
It is available in both tablet and generic forms.
The drug can be prescribed for men aged 18 and above.
Levitra's active ingredient is vardenafil hydrochloride.
It helps achieve erections suitable for sexual activity.
Taking fatty meals may delay the drug's onset.
Levitra does not protect against sexually transmitted diseases.
Use with caution if you have heart conditions.
It is essential to inform your doctor of all medications.
Vardenafil does not cure ED; it manages symptoms.

Vardenafil is primarily metabolized by CYP3A; conivaptan is a moderate CYP3A inhibitor.

Levitra is available in 10 mg and 20 mg tablets.
The medication is not an aphrodisiac; it enhances ability when sexually stimulated.
Vardenafil is a PDE5 inhibitor class drug.
It can be used by men with diabetes-related erectile issues.
Levitra may cause dizziness; avoid driving after taking.
The medication is approved by the FDA for ED treatment.
Do not use if you have severe liver or kidney problems.
Vardenafil should be stored at room temperature, away from moisture.
It is not suitable for women or children.
Consult your doctor for potential drug interactions.

Crizotinib: (Major) Do not use vardenafil orally disintegrating tablets with crizotinib due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets.

Product	Dosage	Quantity + Bonus	Price
Levitra Generic	20mg	270 + 10 Pills	376.33€ 358.41€
Levitra Generic	10mg	60 + 6 Pills	112.98€ 107.60€
Levitra Professional	20mg	30 Pills	119.12€ 113.45€
Levitra Generic	20mg	180 + 10 Pills	293.10€ 279.14€
Levitra Generic	40mg	20 Pills	67.56€ 64.34€
Levitra Generic	60mg	270 + 10 Pills	714.53€ 680.50€
Levitra Generic	10mg	10 Pills	28.93€ 27.55€
Levitra Original	20mg	14 + 2 Pills	102.27€ 97.40€
Levitra Original	20mg	12 Pills	81.99€ 78.09€
Levitra Generic	60mg	20 Pills	81.30€ 77.43€
Levitra Generic	20mg	90 + 8 Pills	180.78€ 172.17€
Levitra Generic	20mg	360 + 10 Pills	458.44€ 436.61€
Levitra Professional	20mg	60 + 2 Pills	223.11€ 212.49€
Levitra Generic	10mg	120 + 10 Pills	178.59€ 170.09€
Levitra Generic	20mg	120 + 10 Pills	224.15€ 213.48€
Levitra Generic	10mg	180 + 10 Pills	246.74€ 234.99€

Vardenafil is primarily metabolized by CYP3A4/5; crizotinib is a moderate CYP3A4 inhibitor.

Frequently Asked Questions

Use reduced doses of no more than 2.5 mg every 72 hours of vardenafil oral tablets with increased monitoring for adverse reactions. Vardenafil is primarily metabolized by CYP3A4/5; atazanavir is a strong CYP3A4 inhibitor. Coadministration with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10 to16-fold. Atazanavir; Cobicistat: (Major) Do not use vardenafil orally disintegrating tablets with atazanavir due to increased vardenafil exposure. (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets.

What are the most common side effects for Stendra?

Vardenafil is primarily metabolized by CYP3A4/5; cobicistat is a strong CYP3A4 inhibitor. Coadministration with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10 to 16-fold. Atomoxetine: (Moderate) Concomitant use of atomoxetine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Bedaquiline: (Major) If possible, avoid the use of vardenafil with bedaquiline due to the risk of QT prolongation. Monitor ECGs if bedaquiline is used in patients receiving other drugs that prolong the QTc interval, such as vardenafil. In addition, vardenafil is associated with QT prolongation.

Parameter	Value	Notes
Onset of Action	25-60 minutes	Typically 30-45 minutes
Duration of Effect	Up to 5 hours	Varies with dose and individual
Half-life	Approximately 4-5 hours	Determines dosing frequency
Time to Peak Concentration	About 60 minutes	After oral administration

Both therapeutic and supratherapeutic doses of vardenafil may produce an increase in QTc interval.

Generic Vardenafil: Availability and Manufacturers

Discontinue bedaquiline if evidence of serious ventricular arrhythmia or if a QTcF interval greater than 500 ms occurs. Both therapeutic (10 mg) and supratherapeutic (80 mg) doses of vardenafil produce an increase in the QTc interval. Berotralstat: (Major) Do not use vardenafil orally disintegrating tablets with berotralstat due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; berotralstat cost levitra uk is a moderate CYP3A4 inhibitor. Bismuth Subcitrate Potassium; Metronidazole; Tetracycline: (Moderate) Concomitant use of metronidazole and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Common Side Effects

Bismuth Subsalicylate; Metronidazole; Tetracycline: (Moderate) Concomitant use of metronidazole and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Brompheniramine; Dextromethorphan; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Brompheniramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Buprenorphine: (Major) Concomitant use of vardenafil and buprenorphine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Buprenorphine; Naloxone: (Major) Concomitant use of vardenafil and buprenorphine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Crizotinib has also been associated with concentration-dependent QT prolongation.

Levitra (Generic Vardenafil) Overview

Vardenafil is primarily metabolized by CYP3A4/5; chloramphenicol is a strong CYP3A4 inhibitor. Chloroquine: (Major) Concomitant use of vardenafil and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Chlorpheniramine; Dextromethorphan; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Chlorpheniramine; Dihydrocodeine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Chlorpheniramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors.

Who should not take vardenafil?

Chlorpromazine: (Major) Concomitant use of vardenafil and chlorpromazine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Ciprofloxacin: (Major) Do not use vardenafil orally disintegrating tablets with ciprofloxacin due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A and ciprofloxacin is a moderate CYP3A inhibitor. Cisapride: (Contraindicated) Avoid concomitant use of vardenafil and cisapride due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. Citalopram: (Major) Concomitant use of citalopram and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Monitor ECGs and electrolytes if crizotinib and vardenafil oral tablets are used together. Cyclosporine: (Major) Do not use vardenafil orally disintegrating tablets with cyclosporine due to increased vardenafil exposure;

How To Get Vardenafil

Aprepitant, Fosaprepitant: (Major) Do not use vardenafil orally disintegrating tablets with aprepitant, fosaprepitant due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; aprepitant is a moderate CYP3A4 inhibitor when administered as a 3-day oral regimen (125 mg/80 mg/80 mg). Coadministration with another moderate CYP3A4 inhibitor increased the AUC of vardenafil by 4-fold. Fosaprepitant is rapidly converted to aprepitant and shares many of the same drug interactions. Monitor for an increase in vardenafil-related adverse effects for several days after administration of a multi-day aprepitant regimen.

Study designs of evaluations included in the review

Aripiprazole: (Moderate) Concomitant use of vardenafil and aripiprazole may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Arsenic Trioxide: (Major) Concomitant use of vardenafil and arsenic trioxide increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Artemether; Lumefantrine: (Major) Concomitant use of vardenafil and lumefantrine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Asenapine: (Major) Concomitant use of vardenafil and asenapine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Atazanavir: (Major) Do not use vardenafil orally disintegrating tablets with atazanavir due to increased vardenafil exposure. do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets.

Brand Name	Active Ingredient	Medication Type	Typical Dosage	Available Forms
Levitra	Vardenafil	PDE5 Inhibitor	5 mg, 10 mg, 20 mg	Tablets
Staxyn	Vardenafil ODT	PDE5 Inhibitor	10 mg	Orally Disintegrating Tablets
Vidalista	Tadalafil (comparison)	PDE5 Inhibitor	2.5 mg, 5 mg, 10 mg	Tablets

Vardenafil is primarily metabolized by CYP3A4/5; cyclosporine is a moderate CYP3A4 inhibitor.

Patient characteristics

Clarithromycin: (Major) Do not use vardenafil orally disintegrating tablets with clarithromycin due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Class IA Antiarrhythmics: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Class IA antiarrhythmics are associated with QT prolongation and torsade de pointes (TdP). Therapeutic and supratherapeutic doses of vardenafil produce an increase in QTc interval. The effect of vardenafil on the QT interval should be considered when prescribing the drug.

What should I do if I miss a dose of vardenafil?

Clofazimine: (Moderate) Concomitant use of clofazimine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Clozapine: (Moderate) Concomitant use of vardenafil and clozapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Cobicistat: (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Codeine; Phenylephrine; Promethazine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors.